Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

PhRMA’s New ‘Let’s Talk About Cost’ Campaign Convenes National Dialogue on Medicine Costs

Washington, DC, September 23, 2017Robert Zirkelbach, Executive Vice President of Public Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), in July posted on the association’s blog, The Catalyst:

Discussions about costs are important. We recognize that many are struggling to access the medicine they need and have important questions about their medicine costs.  And we want to help find the answers.

We recognize that many are struggling to access the medicine they need and have important questions about their medicine costs. And we want to help find the answers.

That is why we are convening a conversation called Let’s Talk About Cost that takes a broad look at this complex issue, exploring the slowdown in medicine cost growth, the rising cost of chronic disease, insurance coverage of medicine, the role of middlemen and what our industry can do to make medicine more affordable for patients.

Questions you may be asking include:

If medicine costs are growing more slowly, why doesn’t it feel that way?

Multiple sources including Express Scripts, the largest pharmacy benefit manager (PBM) in the nation, confirm medicine spending growth was between just 3 and 5 percent in 2016, the slowest rate in years.

Unfortunately, it doesn’t feel that way for patients. That is because out-of-pocket costs for brand medicines have increased 48 percent since 2013.

What is driving up my health care costs?

The biggest cost driver in our health care system is chronic disease.  Patients with chronic diseases, such as cancer, diabetes and heart disease, account for approximately 90 percent of all health care spending and are the leading causes of death and disability in the United States.

Why am I paying more than my insurer for my medicine?

Private payers are reportedly receiving rebates of between 30 percent and 55 percent for medicines to treat a number of conditions, including diabetes, asthma and high cholesterol.

Yet, these negotiated discounts are not shared with patients who pay a deductible or coinsurance for their medicine. No patient should pay more for their medicine than their insurer.

Who decides what I pay for my medicines?

While biopharmaceutical companies set the list price for a brand medicine, more than a third is rebated back to payers and other middlemen in the supply chain. Ultimately, your health insurer determines what you pay for your medicine out of pocket.

How can we make medicine more affordable for patients?

Biopharmaceutical companies offer patient assistance programs that have helped millions of patients access needed medicines for free or nearly free. They are also working with private health insurers to find new ways to pay for medicine that reward outcomes and lower costs for patients.

These and other questions will be featured in print, radio, digital and social channels throughout the year. Advertisements and promotion will run on a variety of platforms nationally.

To learn more about Let’s Talk About Cost and view the advertisements, visit www.PhRMA.org/LetsTalkCost.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives.

Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.